Related Experiment Video
Updated: Oct 10, 2025
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy
Rui-Bo Guo1, Xin-Yue Zhang1, De-Kang Yan1
1School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Shengming 1 Road 77, Double D port, Dalian 116600, China. lixuetao1979@163.com.
Abstract:
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial joint hyperplasia, joint inflammation, cartilage erosion and bone destruction. Macrophages play an essential role in the pathogenesis of RA, and folate receptor β (FR-β) is highly expressed on the surface of activated synovial macrophages in RA patients. Triptolide (TP) has anti-inflammatory properties, and it can protect the cartilage matrix, but its clinical application has been limited due to poor solubility, low bioavailability and systemic toxicity. Therefore, we constructed folate-modified triptolide liposomes (FA-TP-Lips) to target macrophages, thereby treating RA in a safe and effective way. The experiments indicated that FA-TP-Lips had properties of small particle size, uniform particle size distribution, high drug encapsulation and long circulation. Furthermore, FA-TP-Lips showed reduced cytotoxicity, increased cellular uptake and significant anti-inflammatory effects in vitro. It also inhibited osteoclastogenesis. In vivo experiments revealed that liposomes could prolong the circulation of TP in the body, as well as exhibit significant cartilage-protective and anti-inflammatory effects with lower toxicity compared with the free TP group, thereby providing a promising new approach for the treatment of RA.
Insights
Targeted liposomes carrying triptolide (FA-TP-Lips) effectively treat rheumatoid arthritis (RA) by delivering the drug to macrophages. This approach improves drug delivery, reduces toxicity, and offers significant anti-inflammatory and cartilage-protective benefits for RA patients.
Area of Science:
- Drug delivery systems
- Nanomedicine
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease causing joint inflammation and destruction.
- Macrophages are key players in RA pathogenesis, expressing folate receptor beta (FR-β).
- Triptolide (TP) shows anti-inflammatory potential but has poor solubility, bioavailability, and toxicity issues.
Purpose of the Study:
- To develop folate-modified triptolide liposomes (FA-TP-Lips) for targeted delivery to FR-β-expressing macrophages in RA.
- To evaluate the safety and efficacy of FA-TP-Lips as a novel therapeutic strategy for RA.
Main Methods:
- Formulation of FA-TP-Lips with small particle size, high drug encapsulation, and long circulation properties.
- In vitro assessment of cytotoxicity, cellular uptake, and anti-inflammatory effects.
- In vivo evaluation of pharmacokinetics, anti-inflammatory effects, cartilage protection, and toxicity in an RA model.
Main Results:
- FA-TP-Lips demonstrated reduced cytotoxicity and enhanced cellular uptake in vitro.
- Liposomes significantly inhibited osteoclastogenesis and displayed potent anti-inflammatory effects.
- In vivo studies showed prolonged TP circulation, significant cartilage protection, and reduced systemic toxicity compared to free TP.
Conclusions:
- FA-TP-Lips represent a promising targeted drug delivery system for RA treatment.
- This approach enhances triptolide's efficacy and safety profile by targeting activated macrophages.
- FA-TP-Lips offer a novel strategy for managing rheumatoid arthritis with improved therapeutic outcomes.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF